February 18, 2025 09:10 AM EST

Hikma takes Amarin's 'skinny label' fight to the Supreme Court

Alexis Kramer

Pharma Editor

Hikma Pharmaceuticals is asking the US Supreme Court to review a generic drug labeling ruling that it says will “effectively vitiate” a common practice that …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Hikma takes Amarin's 'skinny label' fight to the Supreme Court

Alexis Kramer

Pharma Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

After research pivot, Biogen beefs up pipeline with Stoke's late-stage Dravet candidate

Exclusive: Atomwise, a once high-flying AI startup, taps biotech vet as CEO to lead pared-down company

Pain biotech Latigo eyes up to $150M raise following Vertex's landmark FDA nod

As part of turnaround, Solid Bio reports promising initial data for Duchenne gene therapy

Exclusive: Lux leads $25M Series A in a Lithuanian startup plotting US expansion

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Hik­ma takes Amar­in's 'skin­ny la­bel' fight to the Supreme Court

Pharma Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Hikma takes Amarin's 'skinny label' fight to the Supreme Court